Similar articles

• Clofibrate and related compounds in hyperlipoproteinaemia. A review.

  Gustafson A. Gustafson A. Postgrad Med J. 1975;51(8):suppl 66-71. Postgrad Med J. 1975. PMID: 215983 Review. No abstract available.
• Treating lipid disorders.

  Manninen V, Mälkönen M, Tuomilehto J. Manninen V, et al. Am Heart J. 1979 May;97(5):674-6. doi: 10.1016/0002-8703(79)90197-2. Am Heart J. 1979. PMID: 219673 No abstract available.
• Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy.

  Falko JM, Witztum JL, Schonfeld G, Weidman SW, Kolar JB. Falko JM, et al. Am J Med. 1979 Feb;66(2):303-10. doi: 10.1016/0002-9343(79)90553-9. Am J Med. 1979. PMID: 218451 No abstract available.
• Change of lipoprotein pattern by clofibrate in hyperglyceridaemia and mixed hyperlipidaemia.

  Miettinen TA, Penttilä IM, Lampainen E. Miettinen TA, et al. Acta Med Scand. 1972 Sep;192(3):177-82. doi: 10.1111/j.0954-6820.1972.tb04799.x. Acta Med Scand. 1972. PMID: 4341290 No abstract available.
• Does hypolipidemic therapy prevent coronary heart disease?

  Rifkind BM, Levy RI. Rifkind BM, et al. Cardiovasc Clin. 1974;6(2):1-8. Cardiovasc Clin. 1974. PMID: 4374303 Review. No abstract available.